ISPOR Seventh Annual European Congress

Contributed Poster Presentations Session I


ALLERGY/ASTHMA

 

Cost Studies

PAA1

LEVOCETIRIZINE REDUCES THE COST OF PER AND ITS CO-MORBIDITIES FOR SOCIETY AND EMPLOYERS
Bachert C1, Demarteau N2
1 Ghent University Hospital, Belgium; 2 UCB pharma, Braine-l’Alleud, Belgium

PAA2

PUBLIC HEATH SYSTEM EXPENSES ON CHILDREN’S ATOPIC DERMATITIS TREATMENT IN VLADIVOSTOK CITY
Derkach V, Prosekova E
Far East Branch of Scientific Research Institute of Clinic Immunology, Vladivostok, Russia

PAA3

RESOURCE USE IN PATIENTS WITH EXACERBATIONS OF ASTHMA WITH DIFFERENT UNDERLYING DEGREES OF SEVERITY IN FIVE EUROPEAN COUNTRIES
Piercy J1, Benford M2, Milligan G2, Karavali M2
1 Adelphi Group, Bollington, Cheshire, UK; 2 Adelphi Group Products, Bollington, Cheshire, UK

PAA4

A COMPARATIVE ANALYSIS OF EFFICACY, SAFETY AND COST-EFFECTIVENESS OF SALMETEROL AND MONTELUCAST IN THERAPY OF BRONCHIAL ASTHMA
Hetnal M1, Plisko R1, Landa K1, Glogowski C2, Gierczynski J2
1 HTA Consulting, Krakow, Poland; 2 GlaxoSmithKline Pharmaceuticals S.A, Warszawa, Poland

PAA5

A COMPARATIVE ANALYSIS OF EFFICACY, SAFETY AND COST-EFFECTIVENESS OF FLUTICASONE AND MONTELUCAST IN THERAPY OF BRONCHIAL ASTHMA
Hetnal M1, Plisko R1, Landa K1, Glogowski C2, Gierczynski J2
1 HTA Consulting, Krakow, Poland; 2 GlaxoSmithKline Pharmaceuticals S.A, Warszawa, Poland


Health Policy Studies

PAA6

IMPACT OF A DISEASE MANAGEMENT PROGRAM ON CONTROL OF ASTHMA IN NORMANDY
Launois R1, Salmeron S2, Lançon F3, Perez V4, Gailhardou M3, Roy M4, Magar Y5, Queniart-Stojanovic M3, Godard P6
1 REES France, Paris, France; 2 Hopital Saint Joseph, Paris, France; 3 Fedialis Medica Groupe GSK, Marly Le Roi, France; 4 Caisse Primaire D’Assurance Maladie D’Evreux, Evreux, France; 5 EduSanté, Vanves, France; 6 Centre Hospitalier Universitaire (C.H.U), Montpellier, France

 

Methods

PAA7

A COMPARISON OF TWO APPROACHES TO ESTIMATE ANNUAL MEDICATION COSTS IN THE KORA ASTHMA AND ALLERGY STUDY
Holle R, Stark R, Behrend C, John J
GSF - Research Centre for Environment and Health, Neuherberg, Germany

PAA8

WITHDRAWN

PAA9

WITHDRAWN

 

ARTHRITIS

 

Cost Studies

PAR1

THE BURDEN OF ANKYLOSING SPONDYLITIS IN AUSTRALIA: AN EPIDEMIOLOGICAL AND COST OF ILLNESS MODEL
Stynes G1, Adams J2, Tilden D1, Garrett S3, Wilson J2
1 M-TAG Limited, Hammersmith, UK; 2 M-TAG Pty Limited, Chatswood, NSW, Australia; 3 Schering-Plough Pty Limited, Baulkham Hills, Australia

PAR2

THE TOTAL COST OF TREATMENT AND THE COST-EFFECTIVENESS OF VALDECOXIB VS DICLOFENAC IN THE TREATMENT OF PATIENTS WITH OSTEOARTHRITIS (OA) OF THE HIP AND/OR KNEE
von Scheele B1, Davis KH2, Gaffney L3, Niculescu L4, Verburg KM5
1 RTI Health Solutions, Södra Sandby, Sweden; 2 RTI Health Solutions, Research Triangle Park, NC, USA; 3 RTI Health Solutions, Manchester, UK; 4 Pfizer Inc, New York, NY, USA; 5 Pfizer Inc, Ann Arbor, MI, USA

PAR3

QUANTIFYING DISEASE SEVERITY AS A DETERMINANT OF COSTS AND QUALITY OF LIFE IN PATIENTS WITH ANKYLOSING SPONDYLITIS IN AUSTRALIA
Tilden D1, Stynes G1, Adams J2, Garrett S3
1 M-TAG Limited, Hammersmith, UK; 2 M-TAG Australia Pty Ltd, Chatswood, NSW, Australia; 3 Schering-Plough Pty Limited, Baulkham Hills, Australia

PAR4

THE COART STUDY: THE COST OF OSTEOARTHRITIS IN FRANCE BETWEEN 1991 AND 2002
Le Pen C1, Reygrobellet C1, Gerentes I2
1 Aremis Consultants and Paris Dauphine University, Paris, France; 2 Negma-Lerads Laboratories, Paris, France

PAR5

MESSAGE: AN OBSERVATIONAL POST-LAUNCH STUDY TO ASSESS EFFECTIVENESS AND COST OF SUPLASYN® IN PATIENTS WITH KNEE OSTEOARTHRITIS
Le Pen C1, Ligier M2, Priol G2, Maurel F2, Bacri AM3, Giret d’Orsay G3, Riviere M4, Bard H5, Mazieres B6
1 Aremis Consultants and Paris Dauphine University, Paris, France; 2 Aremis Consultants, Paris, France; 3 Chiesi, France; 4 Bioniche, Canada; 5 Rheumatologist, Paris; 6 Rheumatology Department Rangueil Hospital, Toulouse, France

PAR6

ECONOMIC EVALUATION OF THERAPY WITH NSAID AND WITH COX-2 IN SUBJECTS AGED 66 YEARS OR MORE
Santoni L1, Da Deppo L2, Mantovani LG1
1 University of Milan, Milan, Italy; 2 Pfizer Italia srl, Rome, Italy

PAR7

FIBROMYALGIA COST OF CARE
de Portu S1, Stisi S2, Fedrighi S1, Rossetti F1, Mantovani LG1
1 University of Milan, Milan, Italy; 2 Hospital G.Rummo, Benevento, Italy

PAR8

HEALTH ECONOMIC EVALUATION OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH ADALIMUMAB
Vanoverbeke N1, Annemans L1, Cauchie P2, Hendrickx E2
1 HEDM, Meise, Belgium; 2 Abbott, Ottignies, Belgium

PAR9

A COST MINIMISATION ANALYSE FOR STUDYING THE EFFICIENCY OF BIOLOGIC THERAPIES (BT) IN RHEUMATOID ARTHRITIS (RA). OVERVIEW FOR THE SPANISH SETTING
Badia X1, Serrano D1, Magaz S2
1 Health Outcomes Research Europe, Barcelona, Barcelona, Spain; 2 Health Outcomes Policy and Economics, Barcelona, Spain

PAR10

PATTERNS OF DOSING WITH ADALIMUMAB AMONG COMMERCIALLY INSURED PATIENTS
Ollendorf DA, Lidsky L, Zhao J
PharMetrics, Inc, Watertown, MA, USA

PAR11

A COST EFFICACY ANALYSIS ON ANTI-TNF THERAPY IN ANKYLOSING SPONDYLITIS
Singh G1, Tandon N2, Bala M2
1 Stanford University Medical School, Palo Alto, CA, USA; 2 Centocor, Inc, Horsham, PA, USA

PAR12

HOW ADEQUATE DO RA-PATIENTS REPORT INDIRECT COSTS? – THE EXAMPLE OF A GERMAN COHORT
Mittendorf T1, Merkesdal S2, Greiner W1, Ruof J2
1 University of Hannover, Hannover, Germany; 2 Medical School of Hannover, Hannover, Germany

PAR13

COST-EFFECTIVENESS OF VALDECOXIB COMPARED TO DICLOFENAC IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) IN THE UK (UK) AND GERMANY
Alten RH1, von Scheele B2, Gaffney L3, Maciver F3, Niculescu L4
1 Schlossparkklinik, Berlin, Germany; 2 RTI Health Solutions, Södra Sandby, Sweden; 3 RTI Health Solutions, Manchester, UK; 4 Pfizer Inc, New York, NY, USA

PAR14

COSTS OF RA IN GERMANY ON A MICRO-COSTING LEVEL
Mittendorf T1, Ruof J2
1 University of Hannover, Hannover, Germany; 2 Medical School of Hannover, Hannover, Germany

PAR15

A COMPARISON OF COST OF INFLIXIMAB AND ETANERCEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN ITALY: RESULTS OF THE IERI STUDY GROUP
De Portu S1, Ferraccioli G2, Sarzi-Purrini P3, Fiocco U4, Montecucco C5, Valesini A6, Canesi B7, Leardini G8, Mecchia M9, Mantovani LG1
1 University of Milan, Milan, Italy; 2 Universitŕ Cattolica del Sacro Cuore, Rome, Italy; 3 Ospedale L. Sacco, Milano, Italy; 4 Universitŕ di Padova, Padova, Italy; 5 Universitŕ di Pavia, IRCCS, Policlinico S.Matteo, Pavia, Italy; 6 Universitŕ La Sapienza, Policlinico Umberto I, Roma, Italy; 7 Ospedale Niguarda, Milano, Italy; 8 ULSS12 Venezia, Venezia, Italy; 9 Wyeth, Aprilia, Aprilia, Italy

PAR16

CO-PAYMENTS IN RHEUMATOID ARTHRITIS OBSERVED IN A GERMAN COHORT
Mittendorf T1, Hülsemann JL2, Ruof J2
1 University of Hannover, Hannover, Germany; 2 Medical School of Hannover, Hannover, Germany


Quality of Life/Utility/Preference Studies

PAR17

LINGUISTIC ADAPTATION AND VALIDATION OF THE ARTHRITIS TREATMENT SATISFACTION QUESTIONNAIRE (ARTS) INTO SPANISH
Ruiz M1, Campillo MA2, Monfort J2, Pardo A1, Rejas J3, Soto J3
1 Department of Methodology, College of Psychology, Universidad Autónoma, Madrid, Spain; 2 Department of Rheumatology, Hospital del Mar, Barcelona, Spain; 3 Pfizer SA, Alcobendas, Madrid, Spain

PAR18

ASSESSMENT OF HEALTH STATUS IN A NATIONAL SAMPLE OF U.S. OSTEOARTHRITIC PATIENTS
Gandra SR, Lawrence LW, Humble LJ
The University of Louisiana at Monroe, Monroe, LA, USA

PAR27

ASSESMENT OF QUALITY OF LIFE (QOL) IN ADULTS WITH JUVENILE IDIOPATIC ARTHRITIS (AIJ) DIAGNOSIS IN MéXICO: THE DISABILITY IMPACT

Guzmán Vázquez S1, Soto-Molina H2, Cháidez-Rosales P3, Ilizaliturri-Sánchez VM V3, Duarte-Salazar C3, Nieves-Silva J3, Valero González F3, Aguilera-Zepeda J3, Garduńo Espinosa J2
1 Universidad Autónoma del Estado de México, Toluca, Mexico; 2 Instituto Mexicano Seguro Social, Col. Juarez, Mexico; 3 National Rehabilitation Center (CNR), Col. Arenal de Guadalupe, Mexico

PAR28

ASSESSING INTANGIBLES IN BIOLOGIC THERAPIES FOR RHEUMATOID ARTHRITIS (RA). A WILLINGNESS TO PAY (WTP) STUDY IN SPANISH PATIENTS.

Badia X1, Serrano D1, Magaz S2
1 Health Outcomes Research Europe Group, Barcelona, Spain; 2 Health Outcomes Policy and Economics, Barcelona, Spain


Health Policy Studies

PAR19

SURVEY OF GLOBAL FIBROMYALGIA MANAGEMENT BY FRENCH RHEUMATOLOGISTS IN 2003
Thomas E1, Blotman F1, Myon E2, Taieb C2
1 CHU Montpellier, Montpellier, France; 2 Health Economics & Quality of Life Dept, Boulogne-Billancourt, France

PAR20

PEOPLES PREFERENCES FOR WHO SHOULD GET THE NEXT JOINT REPLACEMENT
Davies LM, Payne K, Fargher EA
University of Manchester, Manchester, UK

PAR21

CROSS-SURVEY OF RHEUMATOLOGISTS AND GP AWARENESS AND KNOWLEDGE OF FIBROMYALGIA
Blotman F1, Thomas E1, Myon E2, Taieb C2
1 CHU Montpellier, Montpellier, France; 2 Health Economics & Quality of Life Dept, Boulogne-Billancourt, France

PAR22

FIBROMYALGIA SYNDROM: A FRENCH EPIDEMIOLOGICAL SURVEY
Myon E, Taieb C
Health Economics & Quality of Life Dept, Boulogne-Billancourt, France

PAR23

SURVEY OF GLOBAL FIBROMYALGIA MANAGEMENT BY FRENCH GENERAL PRACTITIONERS
Thomas E1, Blotman F1, Myon E2, Taieb C2
1 CHU Montpellier, Montpellier, France; 2 Health Economics & Quality of Life Dept, Boulogne-Billancourt, France


Methods

PAR24

RELATIONSHIPS BETWEEN AGE, NUMBER OF PRESCRIPTIONS, AND CO-MORBIDITIES AMONG VA PATIENTS
Raisch DW, Harris CL, Netravali S, Campbell H
VA Cooperative Studies Program, Albuquerque, NM, USA

PAR25

CROSS-VALIDATION OF A NEW QUESTIONNAIRE DESIGNED TO PREDICT FUTURE RISK OF NSAID-INDUCED GASTROINTESTINAL EVENTS
Livengood K, Ambegaonkar A, Craig T
Pfizer Inc, New York, NY, USA

PAR26

COST-UTILITY OUTCOMES SIMULATION MODEL FOR OSTEOARTHRITIS (OA) AND RHEUMATOID ARTHRITIS (RA) PATIENTS (COSMO): DEVELOPMENT AND VALIDATION OF A PHARMACOECONOMIC MODEL
Niculescu L1, Lising AW2, Neumann PJ3
1 Pfizer Inc, New York, NY, USA; 2 Dymaxium Inc, Toronto, ON, Canada; 3 Harvard School of Public Health, Boston, MA, USA

 

CANCER
 

Cost Studies

PCN1

COST-EFFECTIVENESS OF APREPITANT GIVEN WITH STANDARD ANTIEMETICS IN PATIENTS RECEIVING CHEMOTHERAPY IN OFFICE-BASED SETTINGS IN GERMANY
Ehlken B1, Ihbe-Heffinger A2, Bernard R2, Berger K3, Pellissier JM4, Deuson R5
1 MERG, Medical Economics Research Group, Munich, Germany; 2 Klinikum rechts der Isar, Technische Universität München, Munich, Germany; 3 MERG Medical Economics Research Group, Munich, Germany; 4 Merck Research Laboratories, St. Charles, IL, USA; 5 Merck & Co., Inc, Whitehouse Station, NJ, USA

PCN2

COST-EFFECTIVENESS OF IMATINIB (GLEEVEC) AS FIRST-LINE TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
El Ouagari K1, Talbot W1, Baladi JF2
1 Novartis Pharmaceuticals, Dorval, QC, Canada; 2 Novartos Pharmaceuticals, Florham Park, NJ, USA

PCN3

COST-EFFECTIVENESS OF BORTEZOMIB (VELCADE) FOR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Bagust A1, Haycox A1, Mujica-Mota R1, Dhawan R2, Dubois D3
1 University of Liverpool, Liverpool, UK; 2 Johnson & Johnson Pharmaceutical Services LLC, Raritan, NJ, USA; 3 Johnson & Johnson Pharmaceutical Services LLC, Beerse, Belgium

PCN4

COST-UTILITY ANALYSIS OF FULVESTRANT VERSUS EXEMESTANE IN THE SECOND LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER
Ryan J1, Hirsch M2, Knight H1
1 Mapi Values Ltd, Macclesfield, Cheshire, UK; 2 AstraZeneca UK Ltd, Macclesfield, Cheshire, UK

PCN5

COST-UTILITY ANALYSIS OF ANASTROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER (EBC): A UK NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE
Brown R1, Benedict A1, Mansel RE2
1 MEDTAP International Inc, London, UK; 2 University of Wales College of Medicine, Cardiff, UK

PCN6

HOSPITALIZATION COSTS OF PATIENTS WITH INFECTIONS WHO HAVE LUNG CANCER OR NEUTROPENIA IN SWEDEN – A RETROSPECTIVE DATABASE STUDY
Myren KJ
Eli Lilly Sweden AB, Solna, Sweden

PCN7

THE LIFETIME COST OF GEFITINIB (‘IRESSA’) IN TREATING PATIENTS WITH NON-SMALL-CELL LUNG CANCER (NSCLC)
Haiderali A1, Chin W2
1 AstraZeneca Canada Inc, Mississauga, Ontario, Canada; 2 Axia Research Inc, Salt Lake City, UT, USA

PCN8

COST-EFFECTIVENESS ANALYSIS OF ORAL IBANDRONATE VERSUS IV ZOLEDRONIC ACID OR IV GENERIC PAMIDRONATE FOR BONE METASTASES FROM BREAST CANCER IN PATIENTS RECEIVING ORAL HORMONAL THERAPY IN THE UK
De Cock E1, Hutton J1, Barrett-Lee P2, Canney P3, Body JJ4, Neary M5, Lewis G6
1 MEDTAP International Inc, London, UK; 2 Velindre Cancer Centre, Cardiff, UK; 3 Western Hospital, Glasgow, UK; 4 Université Libre de Bruxelles, Brussels, Belgium; 5 Hoffmann-La Roche Inc, Nutley, NJ, USA; 6 Roche Products Limited, Welwyn Garden City, Herts, UK

PCN9

A TIME-IN-MOTION STUDY OF ORAL IBANDRONATE VERSUS IV ZOLEDRONIC ACID FOR THE TREATMENT OF METASTATIC BONE DISEASE IN BREAST CANCER PATIENTS IN THE UK
Wardley A1, Body JJ2, Neary M3, Lewis G4
1 Christie Hospital, Manchester, UK; 2 Université Libre de Bruxelles, Brussels, Belgium; 3 Hoffmann-La Roche Inc, Nutley, NJ, USA; 4 Roche Products Limited, Welwyn Garden City, Herts, UK

PCN10

COST-EFFECTIVENESS-ANALYSIS OF BREAST CANCER DIAGNOSIS WITH CAD (COMPUTER AIDED DETECTION)
Heinen-Kammerer T, Motzkat K, Rychlik R
Institute of Empirical Health Economics, Burscheid, Germany

PCN11

COST-EFFECTIVENESS OF ORAL IBANDRONATE VERSUS IV ZOLEDRONIC ACID OR IV PAMIDRONATE IN THE TREATMENT OF BREAST CANCER WITH BONE METASTASES IN PATIENTS UNDERGOING IV CHEMOTHERAPY IN THE UK
De Cock E1, Hutton J1, Barrett-Lee P2, Canney P3, Body JJ4, Neary M5, Lewis G6
1 MEDTAP International Inc, London, UK; 2 Velindre Cancer Centre, Cardiff, UK; 3 Western Hospital, Glasgow, UK; 4 Université Libre de Bruxelles, Brussels, Belgium; 5 Hoffmann-La Roche Inc, Nutley, NJ, USA; 6 Roche Products Limited, Welwyn Garden City, Herts, UK

PCN12

COST EFFECTIVENESS OF AN ASPIRIN CHEMOPREVENTION AND/OR COLONOSCOPIC SURVEILLANCE IN THE COLORECTAL CANCER
Gerlier L1, Launois R1, Deyra J2, Traissac L3, Chaussade S4, Benamouzig R3
1 REES France, Paris, France; 2 APACC, Paris, France; 3 Hôpital Avicenne, Bobigny, France; 4 Hôpital Cochin, Paris, France

PCN13

COST-EFFECTIVENESS ANALYSIS OF ADVANCED NON-SMALL CELL LUNG CANCER TREATMENT WITH CISPLATIN-ETOPOSIDE, CISPLATIN-WINORELBINE AND CISPLATIN-GEMCYTABINE
Skowron A, Brandys J
Jagiellonian University, Cracow, Poland

PCN14

ALCEA (ADVANCED LUNG CANCER ECONOMIC ASSESSMENT)
Mangone M1, Negrini C2, Perrone F3, Portalone L4, Salvati F5, Zorat PL6
1 Astrazeneca Italy; 2 PBE Consulting, Verona, Italy; 3 Istituto Nazionale Tumori, Napoli, Italy; 4 Ospedale C.Forlanini Roma, Italy; 5 Azienda Ospedaliera S. Camillo Forlanini, Roma, Italy; 6 P.O.Cŕ Foncello, Treviso, Italy

PCN15

GEMZAR RETROSPECTIVE ECONOMIC ANALYSIS OF CLINICAL TRIALS (GREAT2): A PATIENT-LEVEL COST COMPARISON OF THREE CHEMOTHERAPY REGIMENS IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN FRANCE
Launois R1, Avoinet S2, Le Lay K1, Tilden D3, Bhalla S4, Kielhorn A5, Chemali N2
1 REES France, PARIS, France; 2 LILLY, Suresnes, France; 3 M-TAG, Chatswood, New Zealand; 4 European Health Outcomes Research, Windlesham, UK; 5 EDOS Team Leader, Windlesham, Surrey, UK

PCN16

COMPARATIVE COSTS OF GEMCITABINE/CISPLATIN, PACLITAXEL/CARBOPLATIN AND VINORELBINE/CISPLATIN IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN GERMANY
Bischoff H1, Hamann M2, Stynes G3, Bhalla S4, Tilden D3, Kielhorn A4
1 Stabsstelle Medizinisches Management, Heidelberg, Germany; 2 Eli Lilly – Germany, Bad Homburg, Germany; 3 M-TAG Limited, Hammersmith, UK; 4 Eli Lilly, Windlesham, Surrey, UK

PCN17

DOES GEMCITABINE PLUS CISPLATIN PROVIDE VALUE FOR MONEY IN THE TREATMENT OF ADVANCED NON-SMALL-CELL LUNG CANCER IN THE UK?
Watkins J1, Kielhorn A2, Bhalla S2, Tilden D3, Stynes G3
1 Eli Lilly, Basingstoke, UK; 2 Eli Lilly, Windlesham, Surrey, UK; 3 M-TAG Limited, Hammersmith, UK

PCN18

A COST COMPARISON OF GEMZAR PLUS CISPLATIN WITH OTHER NOVEL AGENTS IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN ITALY
Kielhorn A1, Stynes G2, Bhalla S1, Tilden D2
1 Eli Lilly, Windlesham, Surrey, UK; 2 M-TAG Limited, Hammersmith, UK

PCN19

NEW TARGETED THERAPY FOR PATIENTS WITH PREVIOUSLY-TREATED ADVANCED NON-SMALL CELL LUNG CANCER – GEFITINIB (‘IRESSA’)
de Peuter R1, Antonisse A2, van Loon J1, Brown J3
1 Mapi Values, Houten, Netherlands; 2 AstraZeneca BV, Zoetermeer, Netherlands; 3 AstraZeneca, Macclesfield, Cheshire, UK

PCN20

COSTS OF TREATING ADVANCED NON-SMALL-CELL LUNG CANCER IN SPAIN USING GEMCITABINE IN COMBINATION WITH CISPLATIN: A COMPARISON WITH OTHER 2ND GENERATION NOVEL AGENTS
Kielhorn A1, Dilla T2, Stynes G3, Tilden D3, Bhalla S1
1 Eli Lilly, Windlesham, Surrey, UK; 2 Eli Lilly, Madrid, Spain; 3 M-TAG Limited, Hammersmith, UK

PCN21

A PHARMACOECONOMIC MODEL OF THE COST-EFFECTIVENESS OF GEFITINIB (‘IRESSA’) COMPARED WITH BEST SUPPORTIVE CARE (BSC) IN THIRD-LINE TREATMENT OF PATIENTS WITH REFRACTORY ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) IN THE UK
Ratcliffe AE1, Beard S2, Wolowacz S2
1 AstraZeneca, Luton, Bedfordshire, UK; 2 RTI Health Solutions, Manchester, UK

PCN22

A SYSTEMATIC EVALUATION OF THE IMPACT OF THE SCREENING INTERVAL ON EFFECTIVENESS AND COST-EFFECTIVENESS OF DIFFERENT CERVICAL CANCER SCREENING TECHNIQUES.
Sroczynski G1, Aidelsburger P2, Wasem J2, Voigt K3, Gibis B4, Engel J5, Hillemanns P5, Hölzel D5, Goldie SJ6, Siebert U1
1 Harvard Medical School, Boston, MA, USA; 2 University of Duisburg-Essen, Duisburg-Essen, Germany; 3 Institute for Medical Informatics, Biostatistics, and Epidemiology, University of Munich, Munich, Germany; 4 National Association of Statutory Health Insurance Physicians, Berlin, Germany; 5 University of Munich, Munich, Germany; 6 Harvard School of Public Health, Boston, USA

PCN23

A COST MINIMIZATION ANALYSIS OF FIRST-LINE POLYCHEMOTHERAPY REGIMENS IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
Le Lay K1, Riou-França L2, Avoinet S3, Chemali N4, Vergnenčgre A5, Launois R6
1 Rees France, Paris, France; 2 ReesFrance, Paris, France; 3 LILLY FRANCE, Suresnes, France; 4 Lilly, Suresnes, France; 5 Hopital Du Cluzeau, Limoges, France; 6 ReesFrance, Paris, FRANCE, France

PCN24

GEMZAR RETROSPECTIVE ECONOMIC ANALYSIS OF CLINICAL TRIAL (GREAT) IN THE TREATMENT OF NON-SMALL-CELL LUNG CANCER IN TAIWAN
Yang CH1, Wang L2, Wang N3, Kielhorn A4
1 National Taiwan University Hospital, Taipei, Taiwan; 2 Protech Pharmaservices Corporation, Taipei, Taiwan; 3 Eli Lilly and Company Taiwan, Taipei, Taiwan; 4 Eli Lilly Holdings Limited, Surrey, UK

PCN25

COST-EFFECTIVENESS-ANALYSIS OF THE THERAPY OF STAGE T1-T2 PROSTATE CANCER WITH PERMANENT SEED IMPLANTATION IN COMPARISON WITH RADICAL PROSTATECTOMY
Heinen-Kammerer T, Motzkat K, Rychlik R
Institute of Empirical Health Economics, Burscheid, NRW, Germany

PCN26 WITHDRAWN


Quality of Life/Utility/Preference Studies

PCN27

PATIENT PREFERENCE FOR ANASTROZOLE AS ADJUVANT HORMONAL THERAPY FOR EARLY BREAST CANCER (EBC) USING DISCRETE CHOICE WILLINGNESS-TO-PAY (WTP) METHODOLOGY
Wilson J1, Burridge J1, Gniel J2, Maclean A2, LeReun C1, Adams J1, Davey P1
1 M-TAG Australia Pty Ltd, Chatswood, NSW, Australia; 2 AstraZeneca Australia Pty Ltd, NSW, Australia

PCN28

QUALITY OF LIFE AND SEXUALITY IN PATIENTS WITH RECTAL CANCER
Bestmann B1, Schmidt C2, Kuechler T1, Kremer B3
1 Reference Center Quality of Life in Oncology, Kiel, Schleswig-Holste, Germany; 2 Department of General and Thoracic Surgery, Kiel, Schleswig-Holste, Germany; 3 University of Kiel, Kiel, Schleswig-Holste, Germany

PCN29

PROSTATE CANCER SPECIFIC SYMPTOMS IN A GERMAN REFERENCE POPULATION
Bestmann B1, Loetters C2, Weidner W2, Kuechler T1, Rohde V2
1 Reference Center Quality of Life in Oncology, Kiel, Schleswig-Holste, Germany; 2 University of Giessen, Giessen, Hessen, Germany

PCN30

IMPROVED TOXICITY PROFILE OF PEMETREXED VS DOCETAXEL IN PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER PATIENTS TRANSLATES TO COST SAVINGS IN SPAIN
Stynes G1, Aristides M1, Rosell R2, Felip E3, Liepa AM4
1 M-TAG Limited, London, UK; 2 Hospital Germans Trias I Pujol, Barcelona, Spain; 3 Hospital General Universitari Vall d’Hebron, Barcelona, Spain; 4 Eli Lilly and Company, Indianapolis, IN, USA

PCN31

EVALUATION OF PEMETREXED VERSUS DOCETAXEL IN THE SECOND-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER: PATIENT PREFERENCE AND WILLINGNESS-TO-PAY WITH DISCRETE CHOICE CONJOINT ANALYSIS
Brown AJ1, Aristides M1, Fitzgerald PE2, Liepa AM3, Boyer MJ4, Clarke SA4
1 M-TAG Ltd, London, UK; 2 M-TAG Pty Ltd, Chatswood West, New South Wales, Australia; 3 Eli Lilly and Company, Indianapolis, IN, USA; 4 Sydney Cancer Centre, Sydney, Australia

PCN32

INSTRUMENTS TO MEASURE PATIENT-REPORTED OUTCOMES AND PERCEPTIONS OF CANCER-RELATED FATIGUE: A REVIEW OF THE LITERATURE
Baró E1, Herdman MJ1, Gasquet JA2, Sanchez J2
1 3D Health Research, Barcelona, Spain; 2 Amgen, Barcelona, Spain

PCN33

HEALTH UTILITY VALUES FOR CANCER RELATED ANAEMIA
Lloyd A1, Kimberley S1, Cornes P2, Tolley K3
1 MEDTAP International, London, UK; 2 Royal United Hospital Bath, Bath, UK; 3 ORTHO BIOTECH, Buckinghamshire, UK

PCN34

UTILITY ASSOCIATED WITH SEVERITY OF CANCER-RELATED ANAEMIA (CRA): A SOCIETAL VALUATION
Ossa DF1, Briggs A2, Cowell W3, Littlewood T4, Sculpher M5
1 Occam Outcomes, Oxford, UK; 2 HERC – University of Oxford, Oxford, UK; 3 Healthcare Management Group – Roche, Welwyn Garden City, UK; 4 John Radcliffe Hospital, Oxford, UK; 5 University of York, York, UK

PCN35

VALUATION OF SOCIETAL PREFERENCE BETWEEN THERAPIES FOR CANCER-RELATED ANAEMIA (CRA): RECOMBINANT HUMAN ERYTHROPOETIN (RH-EPO) VERSUS BLOOD TRANSFUSION
Ossa DF1, McIntosh E2, Briggs A2, Cowell W3, Littlewood T4, Sculpher M5
1 Occam Outcomes, Oxford, UK; 2 HERC – University of Oxford, Oxford, UK; 3 Healthcare Management Group – Roche, Welwyn Garden City, UK; 4 John Radcliffe Hospital, Oxford, UK; 5 University of York, York, UK


Health Policy Studies

PCN36

THE VALUE OF THE USE OF ANASTROZOLE AS AN ALTERNATIVE ADJUVANT THERAPY FOR EARLY BREAST CANCER (EBC) USING DISCRETE CHOICE WILLINGNESS-TO-PAY (WTP) METHODOLOGY
Wilson J1, Burridge J1, Gniel J2, Maclean A2, LeReun C1, Adams J1, Davey P1
1 M-TAG Australia Pty Ltd, Chatswood, NSW, Australia; 2 AstraZeneca Australia Pty Ltd, NSW, Australia

PCN37

DIFFERENCES IN TREATMENT PRACTICE, RESPONSE RATES AND COST OF EPOETIN ALFA AND DARBEPOETIN ALFA TREATMENT FOR ANEMIC CANCER PATIENTS: A RETROSPECTIVE ANALYSIS FROM SWEDEN
Persson U1, Borg S1, Jansson S1, Ekman T2, Franksson L3, Friesland S3, Larsson AM4
1 IHE, The Swedish Institute for Health Economics, Lund, Sweden; 2 Sahlgrenska University Hospital, Gothenburg, Sweden; 3 Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 4 University Hospital, Malmö, Sweden

PCN38

THE IMPACT OF SCREENING ADHERENCE ON MEDICAL EFFECTIVENESS AND COST-EFFECTIVENESS OF CERVICAL CANCER SCREENING IN GERMANY – A DECISION ANALYSIS
Sroczynski G1, Voigt K2, Gibis B3, Aidelsburger P4, Engel J5, Wasem J4, Hillemanns P5, Hölzel D5, Goldie SJ6, Siebert U1
1 Harvard Medical School, Boston, MA, USA; 2 Institute for Medical Informatics, Biostatistics, and Epidemiology, University of Munich, Munich, Germany; 3 National Association of Statutory Health Insurance Physicians, Berlin, Germany; 4 University of Duisburg-Essen, Duisburg-Essen, Germany; 5 University of Munich, Munich, Germany; 6 Harvard School of Public Health, Boston, USA

PCN39

QUALITY ASSURANCE IN CANCER CHEMOTHERAPY THROUGH PHARMACEUTICAL CARE DOCUMENTATION
Simons S1, Hudson SA2, Macintyre J3, Maclean M4, Jaehde U1
1 Rheinische Friedrich-Wilhelms-Universitaet Bonn, Bonn, NRW, Germany; 2 University of Strathclyde, Glasgow, Glasgow, UK; 3 Western General Hospital, Edinburgh, UK; 4 Western Infirmary, Glasgow, UK

PCN40

DISPARITIES IN MEDICAID CANCER EXPENDITURES
Mullins CD, Snyder SE, Wang J, Cooke JL, Baquet CR
University of Maryland, Baltimore, MD, USA

PCN41

ASSESSMENT OF DIFFERENT STRATEGIES FOR DETERMINING DIAGNOSIS AND RESECTABILITY IN PATIENTS WITH SUSPECTED PANCREATIC CANCER
Schink T1, Boehmig M1, Hur C2, Rosewicz S1, Wernecke KD1, Siebert U2
1 Charité University Hospital, Berlin, Germany; 2 Harvard Medical School, Boston, MA, USA


Methods

PCN42

POOLING CLINICAL AND COST OUTCOMES: A CASE STUDY OF BEST SUPPORTIVE CARE (BSC) IN ADVANCED NON SMALL CELL LUNG CANCER (NSCLC)
McAllister R1, Meddis D2, Jansen J1, Ryan J1, Brown J2
1 MAPI Values Ltd, Bollington, Cheshire, UK; 2 AstraZeneca, Macclesfield, Cheshire, UK

PCN43

MAPPING HEALTH-RELATED QUALITY OF LIFE (HRQOL) MEASUREMENTS INTO GENERIC UTILITY MEASURES (EQ-5D): A CASE STUDY WITH BORTEZOMIB (VELCADE)
Mujica-Mota R1, Bagust A1, Haycox A1, Dhawan R2, Dubois D3
1 University of Liverpool, Liverpool, UK; 2 Johnson & Johnson Pharmaceutical Services LLC, Raritan, NJ, USA; 3 Johnson & Johnson Pharmaceutical Services LLC, Beerse, Belgium

PCN44

META-ANALYSIS OF THE DIAGNOSTIC ACCURACY OF SCREENING TESTS FOR COLORECTAL CANCER
Slivinskas J1, Gagnon YM1, Enns R2
1 Occam Outcomes Ltd, Vancouver, BC, Canada; 2 St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada

PCN45

MODELING EFFECT IN PHARMACOECONOMICS ANALYSIS USING ARTIFICIAL NEURAL NETWORKS
Polak S, Skowron A, Brandys J, Mendyk A
Jagiellonian University, Kraków, Maopolska, Poland

 

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Clinical Outcomes Studies

PCO1

 

DRUG USE PROFILES AFTER HOSPITALIZATION FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN THE NETHERLANDS AND THE RISK ON RE-HOSPITALIZATION
Janse AFC1, Breekveldt-Postma NS1, Erkens JA1, Sandtmann R2, Melilli LE3, Herings RMC4
1 PHARMO Institute, Utrecht, Netherlands; 2 Altana Pharma AG, Konstanz, Germany; 3 Pfizer Inc, New York, NY, USA; 4 PHARMO Institute / Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands

 


Methods

PCO2

 

ITEM SELECTION FOR COPD-SPECIFIC UTILITY INSTRUMENT
Meguro M, Jones PW
St George's Hospital Medical School, London, UK

 

PCO3

 

DEVELOPMENT OF A COPD SEVERITY SCORE IN CLAIMS DATABASE
Wu EQ1, Birnbaum HG1, Cifaldi M2, Colice G3, Kang Y1
1 Analysis Group Inc, Boston, MA, USA; 2 Abbott Laboratories, Abbott Park, IL, USA; 3 Washington Hospital Center, Washington, DC, USA

 

 

CARDIOVASCULAR DISEASES
 

Clinical Outcomes Studies

PCV1

THE COST-EFFECTIVENESS OF IRBESARTAN IN THE TREATMENT OF HYPERTENSIVE TYPE 2 DIABETIC PATIENTS WITH MICROALBUMINURIA IN TAIWAN.
Yang WC1, Annemans L2, Ng YY1, Hwang SJ3
1 Taipei Veterans General Hospital, Taipei, Taiwan; 2 Ghent University, Meise, Belgium; 3 Kaohshiung Medical University Hospital, Kaohsiung, Taiwan

 

PCV2

ACHIEVEMENT OF THE EUROPEAN 1998 LDL-C GOAL BY HYPERCHOLESTEROLAEMIC PATIENTS IN THE STELLAR TRIAL: AN EVIDENCE-BASED MEDICINE (EBM) APPROACH
Edwards SJ, Hadlow S
AstraZeneca UK Ltd, Luton, Bedfordshire, UK

 

PCV3

TIME TO LDL-CHOLESTEROL GOAL ATTAINMENT IN SPAIN
Olivares Q1, Mabe I2, Nocea G3, Alemao E4, Caloto T3, Fosbrook L5, Ahumada C5, Yin D4
1 CS Pedro La Mata, Albacete, Spain; 2 CS Bidezabal, Vizcaya, Spain; 3 Merck, Sharp & Dohme de Espańa, Madrid, Spain; 4 Merck & Co, Whitehouse Station, NJ, USA; 5 Schering Plough, Madrid, Spain

 

PCV4

FIRST ANALYSIS OF CLINICAL SIGNIFICANT INTERACTIONS IN HIGH-RISK CARDIOVSCULAR PATIENTS ENROLLED INTO HOPE-TOO TRIAL IN SLOVAKIA IN THE THIRD YEAR OF TRIAL PARTICIPATION
Foltanova T1, Thurzo M2, Lietava J2, Tumova I1, Lonn E3, Fodor JG4
1Faculty of Pharmacy, Comenius University, Bratislava, Slovakia; 2 2-nd Department of Internal Medicine, Comenius University, Bratislava, Slovakia; 3Hamilton University, Hamilton, ON, Canada; 4University of Ottawa Heart Institute, Ottawa, Canada

 


Cost Studies

PCV79

THE COST-EFFECTIVENESS OF IRBESARTAN IN THE TREATMENT OF HYPERTENSIVE TYPE 2 DIABETIC PATIENTS WITH MICROALBUMINURIA IN CHINA
Hu S1, Chen W1, Annemans L2
1 Fudan University, Shanghai, China; 2 HEDM, Meise, Belgium

 

PCV5

LONG-TERM COST-EFFECTIVENESS OF CLOPIDOGREL® IN PATIENTS WITH ACUTE CORONARY SYNDROME WITHOUT ST-SEGMENT ELEVATION IN GERMANY
Brüggenjürgen B1, Ehlken B2
1 Alpha Care GmbH, Celle, Germany; 2 MERG, Medical Economics Research Group, Munich, Germany

 

PCV6

AN ECONOMIC EVALUATION OF CLOPIDOGREL VS. ASPIRIN IN SECONDARY PREVENTION OF ISCHEMIC EVENTS IN HIGH RISK ATHEROTHROMBOTIC PATIENTS IN ITALY
Rudelli G1, Annemans L2, Spiesser J3, Novelli M4, Walker A5, Gabriel S3
1 Sanofi-Synthelabo, Milan, Italy; 2 HEDM, Meise, Belgium; 3 Sanofi-Synthelabo Recherche, Bagneux, France; 4 Bristol-Myers Squibb, Roma, Italy; 5 Bristol-Myers Squibb, Rueil-Malmaison, France

 

PCV7

THE COST-EFFECTIVENESS OF CLOPIDOGREL IN ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION IN POLAND
Pietrasik A1, Niewada M1, Spiesser J2, Gabriel S3
1 Medical University of Warsaw, Warsaw, Poland; 2 Sanofi-Synthelabo Recherche, Bagneux, France; 3 Sanofi-Synthélabo, Bagneux, France

 

PCV8

THE ECONOMIC IMPACT OF CLOPIDOGREL IN PATIENTS WITH UNSTABLE CORONARY ARTERY DISEASE UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI): POLISH PERSPECTIVE
Pietrasik A1, Niewada M1, Spiesser J2, Gabriel S3
1 Medical University of Warsaw, Warsaw, Poland; 2 Sanofi-Synthelabo Recherche, Bagneux, France; 3 Sanofi-Synthélabo, Bagneux, France

 

PCV9

COST-EFFECTIVENESS ANALYSIS OF ALTEPLASE COMPARED WITH STREPTOKINASE AND ABSENCE OF THROMBOLYTICAL THERAPY FOR MYOCARDIAL INFARCTION
Derkach E, Avxentieva M, Vorobjov P
Moscow medical academy, Moscow, Russia

 

PCV10

THE COST-EFFECTIVENESS OF CLOPIDOGREL IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN SWEDEN: AN ANALYSIS OF PCI-CURE
Lindgren P1, Stenestrand U2, Malmberg K3, Jönsson B4
1 Stockholm Health Economics, Stockholm, Sweden; 2 University Hospital of Linköping, Linköping, Sweden; 3 Karolinska Hospital, Stockholm, Sweden; 4 Stockholm School of Economics, Stockholm, Sweden

 

PCV11

COST EFFECTIVENESS OF ADDING NIASPAN TO ATORVASTATIN TREATMENT IN THE SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE IN PATIENTS WITH DYSLIPIDEMIA IN THE UK
Berger W1, Roze S2, Valentine WJ2, Palmer AJ2
1 Merck KGaA, Darmstadt, Germany; 2 CORE Center for Outcomes Research, Binningen/Basel, Switzerland

 

PCV12

SECONDARY PREVENTION AFTER PCI: THE COST-EFFECTIVENESS OF FLUVASTATIN THERAPY IN THE NETHERLANDS
Chaplin S1, Scuffham P1, Alon M2, Boom van den G2
1 University of York, York, UK; 2 Novartis Pharma, Arnhem, Netherlands

 

PCV13

ECONOMIC ASSESSMENT OF EZETIMIBE CO-ADMINISTRATION IN A HUNGARIAN CHD PATIENT COHORT NOT AT CHOLESTEROL GOAL ON SIMVASTATIN MONOTHERAPY
Hoffer G1, Yin D2, Alemao E2, Nagy L3, Monori M4, Davies GM5, Cook JR5
1 University of Debrecen, Debrecen, Hungary; 2 Merck & Co, Whitehouse Station, NJ, USA; 3 MSD Hungary Kft, Budapest XII, Hungary; 4 Schering Plough, Budapest, Hungary; 5 Merck & Co., Inc, Blue Bell, PA, USA

 

PCV14

AN ECONOMIC ANALYSIS OF CATHETER ABLATION FOR THE TREATMENT OF VENTRICULAR TACHYCARDIA
Reyes C1, Hernandez J1, Duff S2, Knight T2, Calkins H3
1 Boston Scientific, San Jose, CA, USA; 2 Covance Health Economics & Outcomes Services, Gaithersburg, MD, USA; 3 Johns Hopkins Hospital, Baltimore, MD, USA

 

PCV15

COST-EFFECTIVENESS OF LOSARTAN IN PATIENTS WITH HYPERTENSION AND LVH IN SPAIN: AN ECONOMIC EVALUATION BASED ON THE LIFE TRIAL
Ruilope LM1, Burke TA2, Carides GW3, Nocea G4
1 Hospital 12 de Octubre, Madrid, Spain; 2 Merck & Co, Inc, Whitehouse Station, NJ, USA; 3 Merck Research Labs, Blue Bell, PA, USA; 4 MSD Spain, Madrid, Spain

 

PCV16

EVOLUTION OF PRESCRIPTIONS AND DRUG COSTS IN HYPERTENSION – RESULTS FROM A DATABASE FOLLOW-UP STUDY
Berger W1, Annemans L2
1 Merck KgaA, Darmstadt, Germany; 2 Ghent University, HEDM, Meise, Belgium

 

PCV17

COSTS OF HYPERTENSION IN POLAND MEASURED FROM THE THIRD PARTY PAYER PERSPECTIVE IN COMPARISON WITH THE SOCIETAL PERSPECTIVE
Hermanowski T1, Jaworski R2, Czech M2, Pachocki R2
1 Warsaw University of Technology, Warsaw, Poland; 2 Servier Polska, Warsaw, Poland

 

PCV18

COSTS OF HYPERTENSION IN THE ELDERLY IN COMPARISON WITH PATIENTS UNDER 65 IN POLAND
Hermanowski T1, Jaworski R2, Czech M2, Pachocki R2
1 Warsaw University of Technology, Warsaw, Poland; 2 Servier Polska, Warsaw, Poland

 

PCV19

COST-EFFECTIVENESS ANALYSIS OF THE MANAGEMENT OF ARTERIAL HYPERTENSION
Stafilas PC1, Sarafidis PA1, Lasaridis AN1, Aletras VH2, Zouka MD3
1 AHEPA University Hospital, Thessaloniki, Greece; 2 Hellenic Open University, Patra, Greece; 3 Aristotle University of Thessaloniki, Thessaloniki, Greece

 

PCV20

COST EFFECTIVENESS OF ANTIHYPERTENSIVE MONO-THERAPY WITH PERINDOPRIL OR ENALAPRIL IN ELDERLY PATIENTS FROM THE THIRD PARTY PAYER PERSPECTIVE
Hermanowski T1, Jaworski R2, Czech M2, Pachocki R2
1 Warsaw University of Technology, Warsaw, Poland; 2 Servier Polska, Warsaw, Poland

 

PCV21

ECONOMIC EVALUATION OF VARIOUS ANTIHYPERTENSIVE MONOTHERAPIES IN GREECE
Stafilas PC1, Zouka MD2, Sarafidis PA1, Lasaridis AN1, Aletras VH3
1 AHEPA University Hospital, Thessaloniki, Greece; 2 Aristotle University of Thessaloniki, Thessaloniki, Greece; 3 Hellenic Open University, Patra, Greece

 

PCV22

THE COST EFFECTIVENESS OF HORMONE REPLACEMENT THERAPY (HRT) FOR WOMEN WITH MENOPASUAL SYMPTOMS IN SWEDEN
Borgström F1, Zethraeus N2, Johnell O3, Kanis J4, Jönsson B2
1 Stockholm Health Economics, Stockholm, Sweden; 2 Stockholm School of Economics, Stockholm, Sweden; 3 Malmö University Hospital, Malmö, Sweden; 4 University of Sheffield, Sheffield, UK

 

PCV23

ACUTE COSTS OF STROKE IN THE UK NATIONAL HEALTH SERVICE IN 2002-2004
Luengo-Fernandez R1, Gray A1, Mehta Z2, Rothwell P2
1 Oxford University, Oxford, Oxfordshire, UK; 2 Oxford University, UK

 

PCV24

PHARMACOECONOMIC EVALUATION OF THE CIBIS-II TRIAL
Di Stasi F, Scalone L, Mantovani LG
University of Milan, Milan, Italy

 

PCV25

SMOKING CESSATION FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE: A COST-EFFECTIVENESS ANALYSIS
Der Kinderen AJ, Franco OH, De Laet C
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands

 

PCV26

THE COST-EFFECTIVENESS OF EXTENDED ANTITHROMBOTIC PROPHYLAXIS FOLLOWING TOTAL HIP ARTHROPLASTY
Skedgel CD1, Goeree R2, Anderson DR1
1 Dalhousie University, Halifax, NS, Canada; 2 McMaster University, Hamilton, ON, Canada

 

PCV27

COST-EFFECTIVENESS OF BUPROPION IN SMOKING CESSATION IN FINLAND
Hahl J, Jormanainen V
GlaxoSmithKline Oy, Espoo, Finland

 

PCV28

COST-EFFECTIVENESS OF RAMIPRIL IN PATIENTS AT HIGH RISK FOR CARDIOVASCULAR EVENTS: A SWISS PERSPECTIVE
Sendi P1, Russ W2, Battegay E3, Bucher H1
1 Institute for Clinical Epidemiology, Basel, Switzerland; 2 Aventis Pharma AG, Zurich, Switzerland; 3 Outpatient Department of Internal Medicine, Basel, Switzerland

 

PCV29

COST-EFFECTIVENESS OF REDUCTION IN CARDIOVASCULAR OUTCOMES WITH ATORVASTATIN IN PATIENTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL LEVELS, TREATED FOR HYPERTENSION: THE ASCOT-LLA STUDY
Lindgren P1, Buxton MJ2, Kahan T3, Poulter N4, Dahlöf B5, Sever P4, Wedel H6, Jönsson B7
1 Stockholm Health Economics, Stockholm, Sweden; 2 Brunel University, UXBRIDGE, Middlesex, UK; 3 Karolinska Institutet, Stoockholm, Sweden; 4 Imperial College, London, UK; 5 Sahlgrenska University Hospital/Östra, Göteborg, Sweden; 6 Nordic School of Public Health, Göteborg, Sweden; 7 Stockholm School of Economics, Stockholm, Sweden

 

PCV30

COST-EFFECTIVENESS OF N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE IN THE DIAGNOSTIC ASSESSMENT AND MANAGEMENT OF PATIENTS WITH DYSPNEA IN THE EMERGENCY DEPARTMENT
Siebert U, Januzzi JL, Beinfeld MT, Cameron R, Gazelle GS
Harvard Medical School, Boston, MA, USA

 

PCV31

COST OF IN-PATIENT CARE AFTER ADMISSION FOR WARFARIN ASSOCIATED ADVERSE DRUG REACTIONS
Ofori B1, Donnan P1, Goudie B2, Timoney A2, Davey P1
1 University of Dundee, Dundee, UK; 2 NHS Tayside, Dundee, UK

 

PCV32

SOCIOECONOMIC RELEVANCE OF TREATMENT OF CHRONIC HEART FAILURE STAGE NYHA II WITH CRATAEGUS EXTRACT WS® 1442 – A PROSPECTIVE 3-YEAR PHARMACOECONOMIC STUDY
Rychlik R1, Pfeil T1, Daniel D1, Habs M2, Klapper HG2
1 Institute of Empirical Health Economics, Burscheid, Germany; 2 Dr. Willmar Schwabe Arzneimittel, Karlsruhe, Germany

 

PCV33

MODELING THE ECONOMIC IMPACT OF NEW IMPLANTABLE DEFIBRILLATORS WITH A LONGER LIFETIME
Lamarsalle L1, Vainchtock A2, Le Heuzey JY3, Matalon C4, Hazard JR4
1 GYD nstitute – division of IMS Health, Lyon, France; 2 GYD nstitute – division of IMS Health; 3 Hôpital Européen Georges Pompidou; 4 Guidant France SAS

 

PCV34

COST-EFFECTIVENESS OF ANTICOAGULATION WITH BIVALIRUDIN VS. HEPARIN AND GLYCOPROTEIN INHIBITORS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN SWEDEN.
Borg S1, Persson U1, Conradson TB2, Ericsson K2
1 Swedish Institute for Health Economics, Lund, Sweden; 2 Nycomed Group, DK-4000 Roskilde, Denmark

 

PCV35

ECONOMIC ASSESSMENT OF SWITCHING TO EZETIMIBE CO-ADMINISTERED WITH SIMVASTATIN IN SPAIN FOR A COHORT OF PATIENTS NOT AT GOAL ON ATORVASTATIN MONOTHERAPY
Davies GM1, Alemao E2, Nocea G3, Yin D2, Cook JR1
1 Merck & Co., Inc, Blue Bell, PA, USA; 2 Merck & Co, Whitehouse Station, NJ, USA; 3 Merck, Sharp & Dohme de Espańa, Madrid, Spain

 

PCV36

ECONOMIC EVALUATION OF PRIMARY PREVENTION OF CVD EVENTS WITH STATINS IN ITALY
Bustacchini S1, Ruffo P1, Mantovani LG2
1 Pfizer Italia srl, Rome, Italy; 2 University of Milan, Milan, Italy

 

PCV37

ECONOMIC EVALUATION OF TRANSESOPHAGEAL ECHOCARDIOGRAPHY (TEE) GUIDED CARDIOVERSION IN THE ANTICOAGULATION IN CARDIOVERSION USING ENOXAPARIN (ACE) TRIAL FROM THE PERSPECTIVE OF STATUTORY HEALTH INSURANCE (SHI) IN GERMANY
Schädlich PK1, Lehmacher W2, Huppertz E3, Grewe R3, Brecht JG1
1 InForMed GmbH – Outcomes Research and Health Economics, Ingolstadt, Bavaria, Germany; 2 Institute for Medical Statistics, Informatics, and Epidemiology of the University of Cologne, Cologne, NRW, Germany; 3 Aventis Pharma Deutschland GmbH, Bad Soden am Taunus, Hesse, Germany

 

PCV38

COSTS OF MYOCARDIAL INFARCTION TREATMENT IN RUSSIAN FEDERATION
Avxentieva M, Vorobjov P, Sura M
Moscow Medical Academy, Moscow, Russia

 

PCV39

MODELING THE ECONOMIC CONSEQUENCES OF IMPLANTING DUAL CHAMBER VS. SINGLE CHAMBER PACEMAKERS IN THE UK
Caro JJ, Ward AJ
Caro Research Institute, Concord, MA, USA

 

PCV40

COSTS OF ISCHEMIC STROKE TREATMENT IN RUSSIAN FEDERATION
Avxentieva M, Vorobyov P, Sura M
Moscow medical academy, Moscow, Russia

 

PCV41

COST-EFFECTIVENESS OF PHARMACEUTICAL TREATMENTS OF HYPERCHOLESTEROLEMIA IN CATALONIA, SPAIN
Plans-Rubió P
Departament de Sanitat of Catalonia, Barcelona, Spain

 

PCV42

WITHDRAWN

 

PCV43

THE IMPACT OF LOW MOLECULAR WEIGHT HEPARIN (LMWH) ENOXAPARIN USAGE ON OUTCOMES OF TREATMENT MANAGEMENT OF PATIENTS WITH ACUTE CORONARY SYNDROMES (ACS) IN RUSSIA
Vorobiov PA1, Yavelov IS2, Pavlov VE3
1 Russian Society of Pharmacoeconomics and Outcomes Research, Moscow, Russia; 2 Scientific Institute of Physical and Chemical Medicine, Moscow, Russia; 3 Aventis Pharma, Moscow, Russia

 

PCV44

VKA TREATMENT RELATED COSTS IN FRANCE IN PATIENTS WITH CHRONIC NONVALVULAR ATRIAL FIBRILLATION : COST DATA FROM THE INTERNATIONAL STUDY OF ANTICOAGULATION MANAGEMENT (ISAM)
Drouet L1, Duru G2, Mahé I1, Bergmann JF1, Bal dit Sollier C1, Lamarque H3, Gauchoux R4, Woessner M3, Hollowell J5
1 Hôpital Lariboisičre, Paris, France; 2 Université C. Bernard Lyon I, Villeurbanne, France; 3 AstraZeneca, Rueil Malmaison, France; 4 Naxis, Lyon, France; 5 AstraZeneca, Molndal, Sweden

 

PCV45

A SHORT-TERM RETROSPECTIVE ECONOMIC EVALUATION FOR THE TREATMENT OF MILD TO MODERATE ESSENTIAL HYPERTENSION WITH ANGIOTENSIN II-ANTAGONISTS IN SPAIN.
Calvo C1, López Paz JE1, González P2, Del Castillo A3, Rejas J3
1 University Hospital of Santiago de Compostela; 2 Euroclin Institute; 3 Health Outcomes Research, Medical Unit, Pfizer SA, Alcobendas, Madrid, Spain

 

PCV46

SCREENING FOR ABDOMINAL AORTIC ANEURYSM IN MEN. AN ECONOMIC EVALUATION BASED ON A SYSTEMATIC REVIEW OF THE LITERATURE
Wanhainen A1, Lundkvist J2, Bergqvist D1, Björck M1
1 Uppsala University Hospital, Uppsala, Sweden; 2 Karolinska Institutet, Stockholm, Sweden

 

PCV47

DECISION ANALYSIS ON EFFECTIVENESS AND COST-EFFECTIVENESS OF DISEASE MANAGEMENT PROGRAMS FOR THE TREATMENT OF HEART FAILURE
Goehler A1, Dietz R1, Osterziel KJ1, Siebert U2
1 Charitč Campus Virchow Klinikum, Berlin, Germany; 2 Harvard Medical School, Boston, MA, USA

 

PCV48

ARIAL FIBRILLATION HISTORY AND ATRIOVENTRICULAR BLOCK APPEARANCE IN PATIENTS WITH SINUS NODE DISEASE AND SINGLE CHAMBER ATRIAL PACEMAKER – IMPACT ON COST OF THERAPY
Rucinski P1, Kutarski A2
1 Medical University of Lublin, Lublin, Poland, Poland; 2 Medical University of Lublin, Lublin, Poland

 


Quality of Life/Utility/Preference Studies

PCV49

CHRONIC VENOUS DISEASE AND DEPRESSIVE SYMPTOMATOLOGY
Guex JJ1, Myon E2, Marionneau N2, Taieb C2
1 Societe Francaise de Phlebologie, Nice, France; 2 Health Economics & Quality of Life Dept, Boulogne-Billancourt, France

 

PCV50

CHRONIC VENOUS DISEASE: PATIENTS PROFILE
Guex JJ1, Myon E2, Marionneau N2, Taieb C2
1 Societe Francaise de Phlebologie, Nice, France; 2 Health Economics & Quality of Life Dept, Boulogne-Billancourt, France